LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description for typical solid reference material. |
| Solubility | Poorly soluble in water; soluble in DMSO | Solubility depends on solvent, purity, and form. |
| Storage | Cool, dry, protected from light | Long-term storage often uses low temperature and desiccant. |
| Common analytical method | LC-MS/MS | Used for detection and quantification in biological matrices. |
| Common synonyms | GW-501516; GW501516; endurobol | Naming varies among literature, vendors, and databases. |
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
A nanocapsule is a nanoscale shell made from a nontoxic polymer. They are vesicular systems made of a polymeric membrane which encapsulates an inner liquid core at the nanoscale. Nanocapsules have many uses, including promising medical applications for drug delivery, food enhancement, nutraceuticals, and for self-healing materials. The benefits of encapsulation methods are for protection of these substances to protect in the adverse environment, for controlled release, and for precision targeting. Nanoencapsulation is the technique that uses nanocapsules to pack substances to be released in a controlled and effective way. Nanocapsules can be made of various types of nanomaterials; the most common ones are liposomes, nanoparticles, micelles, nanospheres, nanoemulsions and nanocochleates. Nanocapsules can potentially be used as MRI-guided nanorobots or nanobots, although challenges remain.
==== Somogyi rebound ==== Too much insulin may result in a contradictory increase of blood glucose. This "Somogyi effect" is often noted by cat owners who monitor their cat's blood glucose at home. Any time the blood glucose level drops too far to hypoglycemia, the body may defensively dump glucose (converted from glycogen in the liver), as well as hormones epinephrine and cortisol, into the bloodstream. The glycogen raises the blood glucose, while the other hormones may make the cat insulin-resistant for a time. If the body has no glycogen reserves, there will be no rebound effect and the cat will just be hypoglycemic. Rebound hyperglycemia occurs rarely in cats treated with glargine in a protocol aiming for tight control of blood glucose concentrations.
== Early career == He was drafted by Essendon with the second selection in the 2006 AFL draft. Prior to the Draft, Gumbleton was widely seen as one of the top key position players for his age group, and was expected to be Essendon's first pick in the number 2 spot. As a natural centre half-forward player, Gumbleton's imposing figure places him in the immediate spotlight, with North Melbourne recruiting manager Neville Stibbard already talking of an upcoming rivalry between Gumbleton and the third draft pick of the same year, Lachlan Hansen, who has been described as a natural centre half-back.
== Role in hunger circuitry == According to Mark L. Andermann and Bradford B. Lowell: "...AgRP neurons and the wiring diagram within which they operate can be viewed as the physical embodiment of the intervening variable, hunger." Stimulation of neurons expressing AgRP can induce robust feeding behavior in mice that will trigger: increased food consumption, increased willingness to work for food, and increased investigation of food odors. Despite this, AgRP neurons are rapidly inhibited upon food presentation and the onset of eating. One mechanism which may account for this discrepancy is the fact that AgRP neurons signal with Neuropeptide Y in order to allow for sustained feeding behavior that outlasts the activation of the neurons. AgRP neurons are also sensitive to satiety and hunger hormonal signals. One is an appetite stimulant, ghrelin which makes AgRP neurons more excitable through interactions with specialized ghrelin receptors. Another is a satiety signal, leptin, which modulates AgRP activity through inwardly rectifying potassium channels, which alter the excitability of the neurons. Leptin can also decrease the ability of AgRP neurons to carry out other physiological functions, such as triggering Long Term Potentiation of adjacent neurons. Although AgRP neurons can drive many different phases of feeding behavior, separate AgRP neurons project to different areas of the brain, demonstrating a parallel organizational structure.
=== Fijian === A man by the name of Levani Mavoa from the village of Vadravadra on Gau Island is reported to have the longest name in Fiji and possibly the world. His full surname is Mavoaiuluivitimaitaveunienanodralakicakacakatakanavalenilotunagonenivadravadraenaesitetimaiuraqaicuruvularuaenavaleniveivakabulaimaiwaiyevoenayasanakocakaudrove, which is 160 letters long. His surname translates to "injured while on Taveuni when the people of Vadravadra went to work at Ura Estate where he got injured and was later admitted for two months at the Waiyevo Hospital in the province of Cakaudrove".
Sources: en.wikipedia.org
Using any part of a living organism Protein purification involves the isolation of a specific protein of interest from a complex mixture of proteins, often obtained from homogenized cells or tissues. Using parts derived from multicellular organisms (cell culture, tissue culture, and more) In vitro fertilization is used to allow spermatozoa to fertilize eggs in a culture dish before implanting the resulting embryo or embryos into the uterus of the prospective mother. In vitro diagnostics refers to a wide range of medical and veterinary laboratory tests that are used to diagnose diseases and monitor the clinical status of patients using samples of blood, cells, or other tissues obtained from a patient. In vitro pharmacological testing has been used to characterize specific adsorption, distribution, metabolism, and excretion processes of drugs or general chemicals inside a living organism; for example, Caco-2 cell experiments can be performed to estimate the absorption of compounds through the lining of the gastrointestinal tract; The partitioning of the compounds between organs can be determined to study distribution mechanisms; Suspension or plated cultures of primary hepatocytes or hepatocyte-like cell lines (Hep G2, HepaRG) can be used to study and quantify metabolism of chemicals. These ADME process parameters can then be integrated into so called "physiologically based pharmacokinetic models" or PBPK. Cellular models of neurodegenerative diseases allow different ways to probe the health of the mitochondria in the cell. Using cellular or subcellular extracts (e.g.
=== Onset and duration === The onset of action of psilocybin taken orally is 0.5 to 0.8 hours (30 to 50 minutes) on average, with a range of 0.1 to 1.5 hours (5 to 90 minutes). Peak psychoactive effects occur at about 1.0 to 2.2 hours (60 to 130 minutes). The time to offset of psilocybin orally is about 6 to 7 hours on average. The duration of action of psilocybin is about 4 to 6 hours (range 3–12 hours) orally. A small dose of 1 mg by intravenous injection had a duration of 15 to 30 minutes. In another study, 2 mg psilocybin by intravenous injection given over 60 seconds had an immediate onset, reached a sustained peak after 4 minutes, and subsided completely after 45 to 60 minutes.
=== Formation of the T-pilus === To transfer T-DNA into a plant cell, A. tumefaciens uses a type IV secretion mechanism, involving the production of a T-pilus. When acetosyringone and other substances are detected, a signal transduction event activates the expression of 11 genes within the VirB operon which are responsible for the formation of the T-pilus. The pro-pilin is formed first. This is a polypeptide of 121 amino acids which requires processing by the removal of 47 residues to form a T-pilus subunit. The subunit was thought to be circularized by the formation of a peptide bond between the two ends of the polypeptide. However, high-resolution structure of the T-pilus revealed no cyclization of the pilin, with the overall organization of the pilin subunits being highly similar to those of other conjugative pili, such as F-pilus. Products of the other VirB genes are used to transfer the subunits across the plasma membrane. Yeast two-hybrid studies provide evidence that VirB6, VirB7, VirB8, VirB9 and VirB10 may all encode components of the transporter. An ATPase for the active transport of the subunits would also be required.
represents body accelerations acting on the continuum, for example gravity, inertial accelerations, electrostatic accelerations, and so on. In this form, it is apparent that in the assumption of an inviscid fluid – no deviatoric stress – Cauchy equations reduce to the Euler equations. Assuming conservation of mass, with the known properties of divergence and gradient we can use the mass continuity equation, which represents the mass per unit volume of a homogenous fluid with respect to space and time (i.e., material derivative
Sources: en.wikipedia.org
A cancer-associated fibroblast (CAF) (also known as tumour-associated fibroblast; carcinogenic-associated fibroblast; activated fibroblast) is a cell type within the tumor microenvironment that promotes tumorigenic features by initiating the remodelling of the extracellular matrix or by secreting cytokines. CAFs are a complex and abundant cell type within the tumour microenvironment; the number cannot decrease, as they are unable to undergo apoptosis. CAFs have been found to be abundant in a tumour stroma. Myofibroblasts and fibroblasts make up CAFs. The functions of these CAFs have been known to stimulate angiogenesis, supporting the formation of tumours and thus proliferation of cancer cell and metastasis. Cancer cells are usually also drug resistant, which is contributed by CAFs. As such, this interaction is being studied for potential anti-cancer therapy. Normal fibroblasts aid in the production of components of the extracellular matrix such as collagens, fibres, glycosaminoglycans and glycoproteins and are therefore vital in tissue repair in wound healing. CAFs however, are derived from either normal fibroblasts, pericytes, smooth muscle cells, fibrocytes or mesenchymal stem cells These CAFs then go on to support tumour growth by secreting growth factors such as Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF) and Fibroblast Growth Factor (FGF) and other chemokines to stimulate angiogenesis and thus the growth of a tumour.
== Further reading == Degarmo, E. Paul; Black, J T.; Kohser, Ronald A. (2003), Materials and Processes in Manufacturing (9th ed.), Wiley, ISBN 0-471-65653-4. Kalpakjian, Serope; Schmid, Steven R. (2006), Manufacturing Engineering and Technology (5th ed.), Upper Saddle River, NJ: Pearson Prentice Hall, ISBN 0-13-148965-8
== N == Neotropic cormorant - the Uru people domesticated the neotropic cormorant(an aquatic bird). Nixtamalization – the process originated in Mesoamerica, with the earliest evidence of its presence found in Guatemala's southern coast with equipment dated to 1200-1500 BCE.
=== EC 2.7.7: Nucleotidyltransferases === EC 2.7.7.1: nicotinamide-nucleotide adenylyltransferase EC 2.7.7.2: FAD synthase EC 2.7.7.3: pantetheine-phosphate adenylyltransferase EC 2.7.7.4: sulfate adenylyltransferase EC 2.7.7.5: sulfate adenylyltransferase (ADP) EC 2.7.7.6: DNA-directed RNA polymerase EC 2.7.7.7: DNA-directed DNA polymerase EC 2.7.7.8: polyribonucleotide nucleotidyltransferase EC 2.7.7.9: UTP—glucose-1-phosphate uridylyltransferase EC 2.7.7.10: UTP—hexose-1-phosphate uridylyltransferase EC 2.7.7.11: UTP—xylose-1-phosphate uridylyltransferase EC 2.7.7.12: UDP-glucose—hexose-1-phosphate uridylyltransferase EC 2.7.7.13: mannose-1-phosphate guanylyltransferase EC 2.7.7.14: ethanolamine-phosphate cytidylyltransferase EC 2.7.7.15: choline-phosphate cytidylyltransferase EC 2.7.7.16: Now EC 4.6.1.18, pancreatic ribonuclease EC 2.7.7.17: Now EC 4.6.1.19, ribonuclease T2 EC 2.7.7.18: nicotinate-nucleotide adenylyltransferase EC 2.7.7.19: polynucleotide adenylyltransferase EC 2.7.7.20: deleted (identical with EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.21: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.22: mannose-1-phosphate guanylyltransferase (GDP) EC 2.7.7.23: UDP-N-acetylglucosamine diphosphorylase EC 2.7.7.24: glucose-1-phosphate thymidylyltransferase EC 2.7.7.25: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.26: Now EC 4.6.1.24, ribonuclease T1 EC 2.7.7.27: glucose-1-phosphate adenylyltransferase EC 2.7.7.28: nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.29: identical to EC 2.7.7.28, nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.30: fucose-1-phosphate guanylyltransferase EC 2.7.7.31: DNA nucleotidylexotransferase EC 2.7.7.32: galactose-1-phosphate thymidylyltransferase EC 2.7.7.33: glucose-1-phosphate cytidylyltransferase EC 2.7.7.34: glucose-1-phosphate guanylyltransferase EC 2.7.7.35: ribose-5-phosphate adenylyltransferase EC 2.7.7.36: aldose-1-phosphate adenylyltransferase EC 2.7.7.37: aldose-1-phosphate nucleotidyltransferase EC 2.7.7.38: 3-deoxy-manno-octulosonate cytidylyltransferase EC 2.7.7.39: glycerol-3-phosphate cytidylyltransferase EC 2.7.7.40: D-ribitol-5-phosphate cytidylyltransferase EC 2.7.7.41: phosphatidate cytidylyltransferase EC 2.7.7.42: [glutamine synthetase] adenylyltransferase EC 2.7.7.43: N-acylneuraminate cytidylyltransferase EC 2.7.7.44: glucuronate-1-phosphate uridylyltransferase EC 2.7.7.45: guanosine-triphosphate guanylyltransferase EC 2.7.7.46: gentamicin 2′′-nucleotidyltransferase EC 2.7.7.47: streptomycin 3′′-adenylyltransferase EC 2.7.7.48: RNA-directed RNA polymerase EC 2.7.7.49: RNA-directed DNA polymerase EC 2.7.7.50: mRNA guanylyltransferase EC 2.7.7.51: adenylylsulfate—ammonia adenylyltransferase EC 2.7.7.52: RNA uridylyltransferase EC 2.7.7.53: ATP adenylyltransferase EC 2.7.7.54: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.55: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.56: tRNA nucleotidyltransferase EC 2.7.7.57: N-methylphosphoethanolamine cytidylyltransferase EC 2.7.7.58: Now included in EC 6.2.1.71, 2,3-dihydroxybenzoate[aryl-carrier protein] ligase EC 2.7.7.59: [protein-PII] uridylyltransferase EC 2.7.7.60: 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase EC 2.7.7.61: citrate lyase holo-[acyl-carrier protein] synthase EC 2.7.7.62: adenosylcobinamide-phosphate guanylyltransferase EC 2.7.7.63: Now EC 6.3.1.20, lipoate—protein ligase EC 2.7.7.64: UTP-monosaccharide-1-phosphate uridylyltransferase EC 2.7.7.65: diguanylate cyclase EC 2.7.7.66: malonate decarboxylase holo-[acyl-carrier protein] synthase EC 2.7.7.67: CDP-2,3-bis-(O-geranylgeranyl)-sn-glycerol synthase EC 2.7.7.68: 2-phospho-L-lactate guanylyltransferase EC 2.7.7.69: GDP-L-galactose/GDP-D-glucose: hexose 1-phosphate guanylyltransferase EC 2.7.7.70: D-glycero-β-D-manno-heptose 1-phosphate adenylyltransferase EC 2.7.7.71: D-glycero-α-D-manno-heptose 1-phosphate guanylyltransferase EC 2.7.7.72: CCA tRNA nucleotidyltransferase EC 2.7.7.73: sulfur carrier protein ThiS adenylyltransferase EC 2.7.7.74: 1L-myo-inositol 1-phosphate cytidylyltransferase EC 2.7.7.75: molybdopterin adenylyltransferase EC 2.7.7.76: molybdenum cofactor cytidylyltransferase EC 2.7.7.77: molybdenum cofactor guanylyltransferase EC 2.7.7.78: GDP-D-glucose phosphorylase EC 2.7.7.79: tRNAHis guanylyltransferase EC 2.7.7.80: molybdopterin-synthase adenylyltransferase EC 2.7.7.81: pseudaminic acid cytidylyltransferase EC 2.7.7.82: CMP-N,N′-diacetyllegionaminic acid synthase EC 2.7.7.83: UDP-N-acetylgalactosamine diphosphorylase EC 2.7.7.84: diadenylate cyclase EC 2.7.7.85: 2′-5′ oligoadenylate synthase EC 2.7.7.86: cyclic GMP-AMP synthase EC 2.7.7.87: L-threonylcarbamoyladenylate synthase EC 2.7.7.88: GDP polyribonucleotidyltransferase EC 2.7.7.89: [glutamine synthetase]-adenylyl-L-tyrosine phosphorylase EC 2.7.7.90: 8-amino-3,8-dideoxy-''manno''-octulosonate cytidylyltransferase EC 2.7.7.91: valienol-1-phosphate guanylyltransferase EC 2.7.7.92: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate cytidylyltransferase EC 2.7.7.93: phosphonoformate cytidylyltransferase EC 2.7.7.94: Now EC 6.2.1.51, 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 2.7.7.95: Now EC 6.2.1.49, long-chain fatty acid adenylyltransferase FadD28 EC 2.7.7.96: ADP-D-ribose pyrophosphorylase EC 2.7.7.97: 3-hydroxy-4-methylanthranilate adenylyltransferase EC 2.7.7.98: Now EC 6.2.1.50, 4-hydroxybenzoate adenylyltransferase FadD22 EC 2.7.7.99: N-acetyl-α-D-muramate 1-phosphate uridylyltransferase EC 2.7.7.100: SAMP-activating enzyme EC 2.7.7.101: DNA primase DnaG EC 2.7.7.102: DNA primase AEP EC 2.7.7.103: L-glutamine-phosphate cytidylyltransferase EC 2.7.7.104: 2-hydroxyethylphosphonate cytidylyltransferase EC 2.7.7.105: phospho''enol''pyruvate guanylyltransferase EC 2.7.7.106: 3-phospho-D-glycerate guanylyltransferase
The Enzyme Function Initiative (EFI) is a large-scale collaborative project aiming to develop and disseminate a robust strategy to determine enzyme function through an integrated sequence–structure-based approach. The project was funded in May 2010 by the National Institute of General Medical Sciences as a Glue Grant which supports the research of complex biological problems that cannot be solved by a single research group. The EFI was largely spurred by the need to develop methods to identify the functions of the enormous number proteins discovered through genomic sequencing projects.
Sources: en.wikipedia.org
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.
Most methods use liquid chromatography with tandem mass spectrometry. Urine is common in anti-doping testing, and blood or plasma may be used in research.
Typical guidance is cool, dry, dark storage, often at low temperature and with desiccant. Stability data are limited, so storage conditions should be verified for each batch or supplier.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.